Please ensure Javascript is enabled for purposes of website accessibility

ImmunoGen, Inc. Shares Fall After It Outlines Its 2016 Clinical Events Outlook

By Sean Williams - Jan 11, 2016 at 4:16PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares dipped 10% after the company issued a press release examining its 2015 accomplishments and its expectations in 2016.

What: Shares of ImmunoGen (IMGN 0.18%), a biotechnology company focused on the development of antibody-drug conjugates (ADCs) to fight cancer, tumbled as much as 12% during Monday's session. The decline came after the company outlined its advancements in 2015, and offered its expectations for 2016, in a pre-release to its J.P. Morgan Healthcare Conference presentation at 3:00 pm ET. Shares as of 2:50pm ET had bounced slightly off their lows and were down 10%.

So what: As is commonplace with the J.P. Morgan Healthcare Conference, essentially the Super Bowl of healthcare conferences, investors were much more focused on what ImmunoGen has to offer in 2016 than what it delivered in 2015.

With regard to mirvetuximab soravtansine, the company's first folate receptor-targeting ADC, the focus in 2016 is on advancing its FORWARD I and FORWARD II studies which are phase 2 and phase 1b/2, respectively. ImmunoGen plans to meet with regulators in the first half of 2016 to discuss the advancement of FORWARD I into phase 2 in order to potentially gain access to an accelerated approval should it surpass expectations. Shareholders can also look forward to clinical data from a 40-patient ovarian cancer cohort in the second quarter per ImmunoGen's update.

The remainder of the update involved expectations for trial initiations in 2016 for IMGN779, the company's CD33-targeting ADC for acute myeloid leukemia; IMGN529, its CD37-targeting ADC for diffuse-large B-cell lymphoma (DLBCL) and non-Hodgkin lymphoma (NHL) subtypes; and coltuximab ravtansine, a CD19-targeting ADC also for DLBCL and NHL subtypes.

Image source: ImmunoGen.

Now what: Why is ImmunoGen having such a rough go today? It's tough to tell based on the press release, but the entire biotech industry is having a rough day, so that could certainly be playing a part.

Another possible answer is that Wall Street and investors were hoping for a number of clinical updates in 2016, and it appears that ImmunoGen will be spending more time initiating studies in 2016 than reporting on results. Clinical data is what drives the value of biotech stocks, and having to patiently wait for that data can result in some anxious trading, which is what we could be witnessing today.

Looking long-term, ImmunoGen's ADC technology remains a unique way to combat cancer, and ImmunoGen's linking technology caters to the idea of partnerships -- and partnerships bring the potential for upfront cash, milestone payment possibilities, and sales royalties. While not profitable at the moment, ImmunoGen does have more than a dozen unique compounds in clinical development, giving it plenty of promise for the future.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.

The Motley Fool recommends ImmunoGen. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

ImmunoGen, Inc. Stock Quote
ImmunoGen, Inc.
$5.45 (0.18%) $0.01

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.